GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (LTS:0HOJ) » Definitions » Stock Based Compensation

Blueprint Medicines (LTS:0HOJ) Stock Based Compensation : $103.1 Mil (TTM As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Blueprint Medicines Stock Based Compensation?

Blueprint Medicines's Stock Based Compensation for the three months ended in Sep. 2024 was $28.3 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2024 was $103.1 Mil.


Blueprint Medicines Stock Based Compensation Historical Data

The historical data trend for Blueprint Medicines's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Stock Based Compensation Chart

Blueprint Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.65 75.53 91.63 98.97 92.67

Blueprint Medicines Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.07 22.59 24.23 28.02 28.28

Blueprint Medicines Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $103.1 Mil.


Blueprint Medicines Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Blueprint Medicines Business Description

Traded in Other Exchanges
Address
45 Sidney Street, Cambridge, MA, USA, 02139
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.

Blueprint Medicines Headlines

No Headlines